Association between mitogen-activated protein kinase 1 (MAP2K1) gene polymorphisms and the risk of adenocarcinoma during aging in bitches

• Autorzy: Kempisty B. , Zaorska K. , Bukowska D. , Nowak M. , Lange K. , Antosik P. , Brussow K. P. , Nowicki M. , Zabel M.
• Języki publikacji: EN

Abstrakty

EN

Carcinogenesis is often associated with the uncontrolled cell division cycle that leads to the growth and development of cancer. In this study we analyzed the occurrence of MAP2K1 gene polymorphism, which is described as a cell division regulator, in a group of dogs with diagnosed adenocarcinoma and aged group of animals. In this study, blood samples were obtained from 22 female dogs diagnosed with mammary tumors. Moreover, blood samples from geriatric (> 5 to 10-years-old; n = 15), mature adult (> 2 to 5-years-old; n = 10) and young (from 1 to 2-years-old; n = 11) dogs were also collected. 36 bitches diagnosed because of other reasons served as controls. After Sanger sequencing analysis, 15 single nucleotide variations were identified, of which 3 were situated in exons (exon 2, 7 and 11) and the remaining 12 were localized in splice regions of introns. We also observed differences in genotype and allele frequencies between tumor and control groups for heterozygote and for an alternative allele for 3 polymorphisms (c.G267T, g.T72562C, g.T75728C). Moreover, we found higher prevalence of the alternative alleles and/or alternative homozygotes solely in the most advanced age subgroup in comparison with the other two subgroups for two pair of variations: g.A71023G and g.T72440C; g.T75757C and c.C1179T. Although the results in many cases were not statistically significant, we observed different patterns of genetic segregation of alleles in control and tumor-affected subjects, which may serve as a risk factor of cancer occurrence in the investigated group. Moreover, g.T75757C and c.C1179T polymorphisms may be recognized as markers of aging in dogs.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2014
• Tom: 70
• Numer: 08
• Opis fizyczny: p.483-490,fig.,ref.

Twórcy

autor

Kempisty B.

• Department of Histology and Embryology, Medicine Faculty I, Poznan University of Medical Science, 6 Swiecickiego St., 60-781 Poznan, Poland
• Department of Anatomy, Medicine Faculty I, Poznan University of Medical Science, Swiecickiego 6, 60-781 Poznan, Poland

autor

Zaorska K.

• Department of Histology and Embryology, Medicine Faculty I, Poznan University of Medical Science, 6 Swiecickiego St., 60-781 Poznan, Poland

autor

Bukowska D.

• Institute of Veterinary Medicine, Faculty of Animal Breeding and Biology, Poznan University of Life Sciences, Wolynska 35, 60-637 Poznan, Poland

autor

Nowak M.

• Department of Pathology, Faculty of Veterinary Medicine, Wroclaw University of Life Sciences, C.K. Norwida 31, 50-375 Wroclaw, Poland

autor

Lange K.

• Department of Inorganic and Analytical Chemistry, Karol Marcinkowski University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland

autor

Antosik P.

• Institute of Veterinary Medicine, Faculty of Animal Breeding and Biology, Poznan University of Life Sciences, Wolynska 35, 60-637 Poznan, Poland

autor

Brussow K. P.

• Department of Experimental Reproductive Biology, Institute of Reproductive Biology, Leibniz Institute for Farm Animal Biology, Dummerstorf, Germany

autor

Nowicki M.

• Department of Histology and Embryology, Medicine Faculty I, Poznan University of Medical Science, 6 Swiecickiego St., 60-781 Poznan, Poland

autor

Zabel M.

• Department of Histology and Embryology, Wroclaw Medical University, 6a Chalubinskiego St., 50-368, Wroclaw, Poland

Bibliografia

• 1. Ahmad I., Sansom O. J., Leung H. Y.: Advances in mouse models of prostate cancer. Expert Rev. Mol. Med. 2008, 10, e16.
• 2. Antoon J. W., Martin E. C., Lai R., Salvo V. A., Tang Y., Nitzchke A. M., Elliott S., Nam S. Y., Xiong W., Rhodes L. V., Collins-Burow B., David O., Wang G., Shan B., Beckman B. S., Nephew K. P., Burow M. E.: MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS One 2013, 8(8), e69291.
• 3. Baniyash M., Sade-Feldman M., Kanterman J.: Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol. Immunother. 2014, 63(1), 11-20.
• 4. Boohaker R. J., Xu B.: The versatile functions of ATM kinase. Biomed J. 2014, 37(1), 3-9.
• 5. Byers L. A., Wang J., Nilsson M. B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y. H., Diao L., Masrorpour F., Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B. S., Kalhor N., Wistuba I. I., Girard L., Lippman S. M., Mills G. B., Coombes K. R., Weinstein J. N., Minna J. D., Heymach J. V.: Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012, 2(9), 798-811.
• 6. Choi K. S., Kim J. Y., Lim S. K., Choi Y. W., Kim Y. H., Kang S. Y., Park T. J., Lim I. K.: TIS21(/BTG2/PC3) accelerates the repair of DNA double strand breaks by enhancing Mre11 methylation and blocking damage signal transfer to the Chk2(T68)-p53(S20) pathway. DNA Repair (Amst) 2012, 11(12), 965-975.
• 7. Choi Y. L., Soda M., Ueno T., Hamada T., Haruta H., Yamato A., Fukumura K., Ando M., Kawazu M., Yamashita Y., Mano H.: Oncogenic MAP2K1 mutations in human epithelial tumors. Carcinogenesis 2012, 33(5), 956-961.
• 8. Crews C. M., Alessandrini A., Erikson R. L.: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992, 258(5081), 478-480.
• 9. Galler K., Junker K., Franz M., Hentschel J., Richter P., Gajda M., Göhlert A., von Eggeling F., Heller R., Giavazzi R., Neri D., Kosmehl H., Wunderlich H., Berndt A.: Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochem. Cell Biol. 2012, 137(2), 195-204.
• 10. Gao P., Jiao S. C., Bai L., Wang H., Jing F. F., Yang J. L.: Detection of circulating tumour cells in gastric and hepatocellular carcinoma: a systematic review. J. Int. Med. Res. 2013, 41(4), 923-933.
• 11. Godwin P., Baird A. M., Heavey S., Barr M. P., O’Byrne K. J., Gately K.: Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013, 3, 120.
• 12. Guedez L., Jensen-Taubman S., Bourboulia D., Kwityn C. J., Wei B., Caterina J., Stetler-Stevenson W. G.: TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J. Immunother. 2012, 35(6), 502-512.
• 13. Hyland P. L., Lin S. W., Hu N., Zhang H., Wang L., Su H., Wang C., Ding T., Tang Z. Z., Fan J. H., Qiao Y. L., Xiong X., Wheeler W., Giffen C., Yu K., Yuenger J., Burdett L., Wang Z., Chanock S. J., Tucker M. A., Dawsey S. M., Freedman N. D., Goldstein A. M., Abnet C. C., Taylor P. R.: Genetic variants in fast signaling pathway genes and risk of gastric cancer. Int. J. Cancer 2014, 134(4), 822-831.
• 14. Jeet V., Russell P. J., Khatri A.: Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metastasis Rev. 2010, 29(1), 123-142.
• 15. Jugdutt B. I., Jelani A., Palaniyappan A., Idikio H., Uweira R. E., Menon V., Jugdutt C. E.: Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker. Circulation 2010, 122, 341-351.
• 16. Li L., Wang J., Zhang Y., Zhang Y., Ma L., Weng W., Qiao Y., Xiao W., Wang H., Yu W., Pan Q., He Y., Sun F.: MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 2013, 587(24), 3921-3927.
• 17. Li W. Q., Hu N., Wang Z., Yu K., Su H., Wang L., Wang C., Chanock S. J., Burdett L., Ding T., Qiao Y. L., Fan J. H., Wang Y., Xu Y., Giffen C., Xiong X., Murphy G., Tucker M. A., Dawsey S. M., Freedman N. D., Abnet C. C., Goldstein A. M., Taylor P. R.: Genetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population. PLoS One 2013, 8(7), e68999.
• 18. Li Y., Casey S. C., Felsher D. W.: Inactivation of MYC reverses tumorigenesis. J. Intern. Med. 2014, (Epub ahead of print)
• 19. Maniscalco L., Iussich S., Morello E., Martano M., Biolatti B., Riondato F., Della Salda L., Romanucci M., Malatesta D., Bongiovanni L., Tirrito F., Gattino F., Buracco P., De Maria R.: PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology. Vet. J. 2013, 195(1), 41-47.
• 20. Murakami H., Ito S., Tanaka H., Kondo E., Kodera Y., Nakanishi H.: Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis. Anticancer Res. 2013, 33(10), 4299-4307.
• 21. Nowak M., Madej J. A., Dziegiel P.: Expression of E-cadherin, beta-catenin and Ki-67 antigen and their reciprocal relationships in mammary adenocarcinomas in bitches. Folia Histochem. Cytobiol. 2007, 45(3), 233-238.
• 22. Pawłowski K. M., Homa A., Bulkowska M., Majchrzak K., Motyl T., Król M.: Expression of inflammation-mediated cluster of genes as a new marker of canine mammary malignancy. Vet. Res. Commun. 2013, 37(2), 123-131.
• 23. Pawłowski K. M., Maciejewski H., Majchrzak K., Dolka I., Mol J. A., Motyl T., Król M.: Five markers useful for the distinction of canine mammary malignancy. BMC Vet. Res. 2013, 9, 138.
• 24. Pinzani P., Scatena C., Salvianti F., Corsini E., Canu L., Poli G., Paglierani M., Piccini V., Pazzagli M., Nesi G., Mannelli M., Luconi M.: Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. J. Clin. Endocrinol. Metab. 2013, 98(9), 3731-3738.
• 25. Rattani A., Vinod P. K., Godwin J., Tachibana-Konwalski K., Wolna M., Malumbres M., Novák B., Nasmyth K.: Dependency of the spindle assembly checkpoint on cdk1 renders the anaphase transition irreversible. Curr. Biol. 2014, 24(6), 630-637.
• 26. Reznik R., Hendifar A. E., Tuli R.: Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front Physiol. 2014, 5, 87.
• 27. Scarpa A., Sikora K., Fassan M., Rachiglio A. M., Cappellesso R., Antonello D., Amato E., Mafficini A., Lambiase M., Esposito C., Bria E., Simonato F., Scardoni M., Turri G., Chilosi M., Tortora G., Fassina A., Normanno N.: Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 2013, 8(11), e80478.
• 28. Shcherba M., Liang Y., Fernandes D., Perez-Soler R., Cheng H.: Cell cycle inhibitors for the treatment of NSCLC. Expert Opin Pharmacother 2014, (Epub ahead of print)
• 29. Vázquez-Novelle M. D., Sansregret L., Dick A. E., Smith C. A., McAinsh A. D., Gerlich D. W., Petronczki M.: Cdk1 inactivation terminates mitotic checkpoint surveillance and stabilizes kinetochore attachments in anaphase. Curr. Biol. 2014, 24(6), 638-645.
• 30. Vitolo D., Palmieri M. B., Ruco L. P., Rendina E., Bonsignore G., Baroni C. D.: Cytokine production and expression of adhesion molecules and integrins in tumor infiltrating lymphomononuclear cells of non-small cell carcinomas of the lung. Am. J. Pathol. 1994, 145(2), 322-329.
• 31. Volonté A., Di Tomaso T., Spinelli M., Todaro M., Sanvito F., Albarello L., Bissolati M., Ghirardelli L., Orsenigo E., Ferrone S., Doglioni C., Stassi G., Dellabona P., Staudacher C., Parmiani G., Maccalli C.: Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J. Immunol. 2014, 192(1), 523-532.
• 32. Wang J., Zhang K. Y., Liu S. M., Sen S.: Tumor-associated circulating micro-RNAs as biomarkers of cancer. Molecules 2014, 19(2), 1912-1938.
• 33. Waterfall J. J., Arons E., Walker R. L., Pineda M., Roth L., Killian J. K., Abaan O. D., Davis S. R., Kreitman R. J., Meltzer P. S.: High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat. Genet. 2014, 46(1), 8-10.
• 34. Zhao W., Yang Z., Liu X., Tian Q., Lv Y., Liang Y., Li C., Gao X., Chen L.: Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis. J. Int. Med. Res. 2013, 41(3), 573-583.

Uwagi

Rekord w opracowaniu